Timing of Antiretroviral Therapy for HIV-1 Infection and TuberculosisDiane V. Havlir, Ian Sanne, Evelyn Hogg et al.|New England Journal of Medicine|2011Cited by 541
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D. Hughes, Justin Ritz et al.|The Lancet HIV|2019Cited by 39
Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy VolunteersKelly E. Dooley, Radojka M. Savić, Jeong‐Gun Park et al.|Antimicrobial Agents and Chemotherapy|2015Cited by 21
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D. Hughes, Robert A. Salata et al.|Journal of the International AIDS Society|2022Cited by 13
Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settingsTanakorn Apornpong, Monica Gandhi, Beatriz Grinsztejn et al.|AIDS|2021Cited by 5